Company news

BioVie Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

BioVie Announces FDA Authorization to Initiate Phase 2 Trials Assessing NE3107’s Pro-motoric Activity in Parkinson’s Disease

October 25, 2021

BioVie Inc. Announces Closing of Public Offering of Common Stock

August 10, 2021

BioVie Inc. Announces Pricing of Public Offering of Common Stock

August 7, 2021

BioVie Inc. Announces Proposed Public Offering of Common Stock

August 5, 2021

BioVie Announces First Patient Enrolled in Phase 3 Study of NE3107 in Alzheimer’s Disease

August 4, 2021

BioVie Presents Data Supporting use of NE3107 in the Treatment of Alzheimer’s Disease at 2021 Alzheimer’s Association International Conference

July 26, 2021

BioVie Announces First Patient Enrolled in BIV201 Phase 2b Clinical Trial for Ascites

June 23, 2021

BioVie Receives FDA Guidance for Phase 3 Clinical Trial of BIV201 in HRS-AKI

June 22, 2021

BioVie Announces Closing of Acquisition of BioPharma Assets from Privately Held NeurMedix

June 10, 2021

BioVie Announces Amended Terms for Asset Acquisition from Privately Held NeurMedix

May 9, 2021

BioVie Acquires Biopharma Assets from Privately Held NeurMedix

April 26, 2021

BioVie Commences Patient Screening in Phase 2 Clinical Trial

March 8, 2021

BioVie Announces Closing of Public Offering of Common Stock

September 22, 2020

BioVie Inc. Announces Nasdaq Listing and Pricing of $15.7 Million Public Offering

September 16, 2020

Highly Accomplished Executives Join BioVie’s Board of Directors

June 15, 2020

BioVie Advances the BIV201 Clinical Program and Prefilled Syringe

June 10, 2020

BioVie Submits Protocol for Phase 2b/3 Refractory Ascites Study to FDA

October 21, 2019

← Newer news releases

Decks

The 5 newest of 24 decks. Every deck is listed under its year.